168 related articles for article (PubMed ID: 38454247)
21. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
22. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.
Ochiana SO; Pandarinath V; Wang Z; Kapoor R; Ondrechen MJ; Ruben L; Pollastri MP
Eur J Med Chem; 2013 Apr; 62():777-84. PubMed ID: 22889561
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Borthakur G; Dombret H; Schafhausen P; Brummendorf TH; Boissel N; Jabbour E; Mariani M; Capolongo L; Carpinelli P; Davite C; Kantarjian H; Cortes JE
Haematologica; 2015 Jul; 100(7):898-904. PubMed ID: 25887498
[TBL] [Abstract][Full Text] [Related]
24. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer.
Wang Z; Song W; Aboukameel A; Mohammad M; Wang G; Banerjee S; Kong D; Wang S; Sarkar FH; Mohammad RM
Int J Cancer; 2008 Aug; 123(4):958-66. PubMed ID: 18528859
[TBL] [Abstract][Full Text] [Related]
25. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.
Zi D; Zhou ZW; Yang YJ; Huang L; Zhou ZL; He SM; He ZX; Zhou SF
Int J Mol Sci; 2015 Nov; 16(11):27228-51. PubMed ID: 26580601
[TBL] [Abstract][Full Text] [Related]
26. ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Liu J; Hong J; Ahn KS; Go J; Han H; Park J; Kim D; Park H; Koh Y; Shin DY; Yoon SS
Leuk Lymphoma; 2019 Oct; 60(10):2532-2540. PubMed ID: 30947576
[TBL] [Abstract][Full Text] [Related]
27. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
28. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
29. Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Li J; Luo M; Wang Y; Shang B; Dong L
Oncol Rep; 2016 Sep; 36(3):1345-52. PubMed ID: 27430377
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
32. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
33. A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor.
Zhu Q; Yu X; Zhou ZW; Luo M; Zhou C; He ZX; Chen Y; Zhou SF
J Cancer; 2018; 9(12):2061-2071. PubMed ID: 29937924
[TBL] [Abstract][Full Text] [Related]
34. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
35. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
36. The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines.
Xie L; Meyskens FL
Melanoma Res; 2013 Apr; 23(2):102-13. PubMed ID: 23344158
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
38. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
Zhang Y; Ma Y; Wang Y; Mukhopadhyay D; Bi Y; Ji B
Pancreatology; 2022 Jun; 22(5):619-625. PubMed ID: 35550115
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
Kalu NN; Mazumdar T; Peng S; Tong P; Shen L; Wang J; Banerjee U; Myers JN; Pickering CR; Brunell D; Stephan CC; Johnson FM
Cancer Lett; 2018 Sep; 431():64-72. PubMed ID: 29807113
[TBL] [Abstract][Full Text] [Related]
40. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.
Xie L; Kassner M; Munoz RM; Que QQ; Kiefer J; Zhao Y; Mousses S; Yin HH; Von Hoff DD; Han H
Biochem Pharmacol; 2012 Feb; 83(4):452-61. PubMed ID: 22100984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]